Tuesday, May 7, 2024
5/7/2024
Project Summary/Abstract For pediatric patients with RAS-mutated tumors, clinical trials testing targeted therapies are limited due to the paucity of preclinical data. This is unfortunate, as targeted therapies have the potential to make a significant impact on morbidity for pediatric patients. Cytotoxic agents significantly delay normal childhood development leading to lifelong sequalae. In contrast, targeted therapies that preferentially attack RAS-mutated tumor cells while sparing normal developing tissue can limit unwanted sequalae and enhance overall outcomes for pediatric cancer patients. Unfortunately, single-agent targeting of RAS-mutated cancer cells using either MEK inhibitors or mutant RAS inhibitors is largely ineffective; resistance rapidly develops due to upregulation of multiple RTKs and subsequent hyperactivation of WT RAS signaling. Thus, alternative therapeutic approaches are needed to treat RAS-mutated pediatric cancers. Toward this end, we take two complementary approaches at inhibiting WT RAS signaling designed to enhance the effectiveness of targeted therapies in RAS-mutated pediatric cancers. While each approach seems obvious in hindsight, neither has been tested in pre-clinical models of RAS-mutated pediatric cancers. We first examine the extent to which broad inhibition of proximal RTK signaling using inhibitors to the common proximal RTK signaling intermediates SHP2 or SOS1 enhances the efficacy of and delays therapeutic resistance to MEK or mutant RAS inhibitors in RAS-mutated non-CNS pediatric cancer cells. Since MEK inhibition induces compensatory RTK-dependent signaling cascades, co-targeting RTK signaling with MEK is an attractive approach to treat RAS-mutated pediatric cancers. However, studies in multiple RAS-mutated cancers revealed that the specific RTK that is reactivated can vary between cell lines or studies, even within the same cancer type. Thus, rather than using specific RTK inhibitors that may differ for each patient, we inhibit the common proximal RTK signaling intermediates SHP2 or SOS1, and use both pharmacologic and drug resistance assays to determine which drug-drug combinations are the most potent at enhancing drug killing and inhibiting therapeutic resistance. We then test the most promising therapeutic combinations in patient-derived xenograft models. As a second approach, we determine the extent to which combined inhibition of mutant RAS and WT RAS effector signaling enhances the efficacy of and delays therapeutic resistance to mutant RAS inhibitors in RAS- mutated non-CNS pediatric cancer cells. RAS proteins show differential activation of RAF and PI3K pathways: HRAS potently activates PI3K but poorly activates RAF, whereas KRAS potently activates RAF but poorly activates PI3K. Since both MEK and PI3K pathways must be inhibited for effective killing of RAS-mutated pediatric cancers, we use this fundamental understanding of signaling differences between mutant RAS family members to examine rational therapeutic approaches in RAS-mutated non-CNS pediatric cancer cells. We then test the most promising therapeutic combinations in patient-derived xenograft models.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
